WBB Securities Initiates Coverage On Paratek Pharmaceuticals with Speculative Buy Rating, Announces $6 Price Target

WBB Securities analyst Stephen Brozak initiates coverage on Paratek Pharmaceuticals (NASDAQ:PRTK) with a Speculative Buy rating and a $6 price target.

Benzinga · 01/08/2020 14:22

WBB Securities analyst Stephen Brozak initiates coverage on Paratek Pharmaceuticals (NASDAQ:PRTK) with a Speculative Buy rating and a $6 price target.